Wellington Management Group LLP decreased its stake in shares of Cambrex Corporation (NYSE:CBM) by 40.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,488 shares of the biotechnology company’s stock after selling 30,187 shares during the period. Wellington Management Group LLP owned approximately 0.14% of Cambrex Corporation worth $2,449,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in the stock. First National Bank of Omaha boosted its position in Cambrex Corporation by 60.2% in the first quarter. First National Bank of Omaha now owns 14,963 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 5,625 shares during the period. State Street Corp boosted its position in Cambrex Corporation by 5.3% in the fourth quarter. State Street Corp now owns 689,513 shares of the biotechnology company’s stock valued at $37,198,000 after buying an additional 34,532 shares during the period. FMR LLC boosted its position in Cambrex Corporation by 44.7% in the fourth quarter. FMR LLC now owns 504,448 shares of the biotechnology company’s stock valued at $27,214,000 after buying an additional 155,753 shares during the period. State Board of Administration of Florida Retirement System boosted its position in Cambrex Corporation by 123.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 50,931 shares of the biotechnology company’s stock valued at $2,804,000 after buying an additional 28,115 shares during the period. Finally, First Trust Advisors LP acquired a new position in Cambrex Corporation during the first quarter valued at approximately $1,154,000. Institutional investors own 98.28% of the company’s stock.
Shares of Cambrex Corporation (NYSE CBM) opened at 59.00 on Thursday. The company has a market capitalization of $1.92 billion, a PE ratio of 22.46 and a beta of 2.28. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The firm has a 50-day moving average price of $58.61 and a 200-day moving average price of $55.24.
Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.17. The business had revenue of $105.01 million for the quarter, compared to analyst estimates of $99.05 million. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. Cambrex Corporation’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.50 EPS. Equities analysts anticipate that Cambrex Corporation will post $3.02 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/07/27/cambrex-corporation-cbm-shares-sold-by-wellington-management-group-llp-updated.html.
Several brokerages recently issued reports on CBM. Zacks Investment Research cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $64.00.
In related news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $54.19, for a total value of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Leon J. Hendrix, Jr. sold 20,656 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total value of $1,155,703.20. Following the completion of the sale, the director now directly owns 74,662 shares in the company, valued at approximately $4,177,338.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 70,656 shares of company stock worth $4,026,143. 2.48% of the stock is owned by insiders.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.